Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Mevo Health

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Mevo Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 314 · Grade C

Mevo Health

Visit Mevo Health Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Mevo Health a bad call — it's best for readers considering provider-reviewed injection care who obtain the exact term, medication supply and patient payment agreement first. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
66
Supply Reliability
95
61
Transparency
90
72
Access Breadth
93
56
Clinical Oversight
92
68
Track Record
88
53
CoreAge RxBrief Score 94 · 63Mevo Health

Price, coverage & the tracker

CoreAge RxMevo Health
Brief Score94/100 (A)63/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Advertised injection from $199/month

Current homepage names compounded injections; full selected term, payment and supplied quantity unconfirmed.

Confirm the patient agreement and refund cutoff. A projected oral-results graphic does not establish an oral medication offer.

Full price details

Compounded semaglutide injections advertised; complete selected-plan quote unknown; current homepage starts at $199/month without a full selected commitment or supplied quantity

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Advertised injection from $259/month

Monthly, quarterly and six-month choices described; full longer-plan charge and selected supply unconfirmed. Monthly shipment and provider access advertised.

Cancellation before next billing cycle described; precise advance deadline and unused-prepaid refund calculation unconfirmed.

Full price details

Compounded tirzepatide injections advertised; complete selected-plan quote unknown; current treatment page starts at $259/month with monthly, quarterly and six-month choices but no full selected longer-term payment

CoverageUS only; restrictions by state, confirmed at intakeAvailable only in U.S. states where the service and treating clinician operate; complete treatment-state list unconfirmed
Brand-name accessNot confirmedBrand ingredient comparisons do not establish a named branded GLP-1 prescribing service.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Mevo Health: Advertised injection starts at $199/$259 monthly. Full selected payment, supply and refund agreement remain unconfirmed; an oral-results projection is not a verified product offer.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.